<DOC>
	<DOCNO>NCT00154349</DOCNO>
	<brief_summary>The objective study determine efficacy safety imatinib mesylate patient diagnose Philadelphia chromosome positive acute lymphocytic leukemia ( ALL ) .</brief_summary>
	<brief_title>Efficacy Study Imatinib Mesylate Treat Philadelphia-Positive Acute Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients histologically confirm diagnosis ALL . Patients confirm Ph chromosome positive bcrabl gene positive . Patients relapse Patients refractory initial remission induction therapy Patients ineligible initial remission induction therapy Patients ECOG Performance Status Score 0 2 Serum creatinine concentration 2 × upper limit normal range ( ULN ) AST ( SGOT ) ALT ( SGPT ) 3 × ULN . In patient hepatic dysfunction leukemic involvement , AST ( SGOT ) ALT ( SGPT ) 5 × ULN Serum bilirubin level 3 × ULN Patients finding indicative leukemic involvement central nervous system Patients serious concomitant medical condition ( e.g. , poorly controllable infection , interstitial pneumonia , pulmonary fibrosis , congestive cardiac failure , poorly control diabetes mellitus , mental disorder ) Patients expect receive hematopoietic stem cell transplantation within 6 week plan initiation study drug Patients receive hematopoietic stem cell transplantation Grade 3 4 GVHD . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ph+ALL</keyword>
	<keyword>imatinib mesylate</keyword>
</DOC>